MedTrace Logo

An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)

NCT01075477 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 151

Last updated 2016-11-02

No results posted yet for this study

Summary

This observational study will assess the execution, efficacy and safety of treatment with MabThera in patients with rheumatoid arthritis. Data from patients receiving MabThera according to local treatment guidelines will be collected for 29 months. Target sample size is 100-200 patients.

Conditions

Interventions

DRUG

rituximab [Mabthera/Rituxan]

As prescribed by physician

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075477 on ClinicalTrials.gov